Robert P. Webb
United States Department of the Army
15 Papers
81 Citations
Robert P. Webb is an academic researcher from United States Department of the Army. The author has contributed to research in topics: Clostridium botulinum & Botulism. The author has an hindex of 7, co-authored 15 publications.
Chat about Author
Papers
A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.
Jean Mukherjee,Jacqueline M. Tremblay,Clinton E. Leysath,Kwasi Ofori,Karen Baldwin,Xiaochuan Feng,Daniela Bedenice,Robert P. Webb,Patrick M. Wright,Leonard A. Smith,Saul Tzipori,Charles B. Shoemaker +11 more
TL;DR: A single, easy-to-produce recombinant protein was as efficacious as polyclonal antiserum in a clinically-relevant mouse model of botulism and should have widespread application in antitoxin development and other therapies in which neutralization and/or accelerated clearance of a serum biomolecule can offer therapeutic benefit.
Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.
TL;DR: Differences in protective immunity diminished after multiple vaccinations with either ciBoNT/A1 HP or BoNT/ a1 H(c), and the survival rates were more comparable at the toxin levels used to challenge.
73
Protection with Recombinant Clostridium botulinum C1 And D Binding Domain Subunit (Hc) Vaccines Against C and D Neurotoxins
Robert P. Webb,Theresa J. Smith,Patrick M. Wright,Vicki A. Montgomery,Michael M. Meagher,Leonard A. Smith +5 more
TL;DR: Results indicate the recombinant C1 and D Hc vaccines are not only effective in a monovalent formula but offer complete protection against both parental and C/D mosaic toxin and partial protection against D/C mosaic toxin when delivered as a bivalent vaccine.
66
What next for botulism vaccine development
Robert P. Webb,Leonard A. Smith +1 more
TL;DR: This review focuses on the development of a recombinant bivalent vaccine (rBV A/B) composed of purified recombinant BoNT/A andBoNT/B receptor-binding domain proteins, as well as presenting a summary of progress and issues associated with alternative vaccines currently being developed against botulism.
Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
Robert P. Webb,Theresa J. Smith,Leonard A. Smith,Patrick M Wright,Rebecca L Guernieri,Jennifer L Brown,Janet C Skerry +6 more
TL;DR: The results suggest the ciBoNT HP vaccines exhibit superior potency after single vaccinations but multiple vaccinations with BoNT/Hc antigens resulted in increased survival rates at the toxin challenge levels used.
40